A study to evaluate the efficacy of proactive therapy with topical agents and antihistamines during the maintenance phase of atopic dermatitis.

A study to evaluate the efficacy of proactive therapy with topical agents and antihistamines during the maintenance phase of atopic dermatitis. - A study to evaluate the efficacy of proactive therapy with topical agents and antihistamines during the maintenance phase of atopic dermatitis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017536

Enrollment

200

Registered

2015-05-14

Start date

2015-02-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

Proactive therapy with topical agents alone. Proactive therapy with topical agents plus antihistamines.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with atopic dermatitis and who had moderate or severe atopic eczema in the recent 12 weeks. 2) Patients with less than mild score who are well controlled with standard therapy defined in the JDA guideline. *controlled without steroids anc tacrolimus treatment. *TARC level is less than 700pg/mL 3) Patients providing written consent after receiving explanation regarding the details of this study. 4) Patients aged 16 years or older at enrollment; for those under the age of 20 years, consent from their legal guardians (e.g., their parents) is required.

Exclusion criteria

Exclusion criteria: 1) Patients who have the history of hypersensitivity to any of the study drug. 2) Pregnant or possibly pregnant women, or breastfeeding women. Women who wish to become pregnant during study participation. 3) Patients who are judged inappropriate to participate in the study by the investigator.

Design outcomes

Primary

Measure	Time frame
Remission maintenance rate	—

Countries

Japan

Contacts

Public ContactNaomi Kanazawa

EBC&M LLC. Project planning & Development department

kanazawa@ebc-m.com03-6435-3833

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026